Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 22

1.

A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms.

Wade DT, Robson P, House H, Makela P, Aram J.

Clin Rehabil. 2003 Feb;17(1):21-9.

PMID:
12617376
2.
3.

Acute effects of a single, oral dose of d9-tetrahydrocannabinol (THC) and cannabidiol (CBD) administration in healthy volunteers.

Martin-Santos R, Crippa JA, Batalla A, Bhattacharyya S, Atakan Z, Borgwardt S, Allen P, Seal M, Langohr K, Farré M, Zuardi AW, McGuire PK.

Curr Pharm Des. 2012;18(32):4966-79. Review.

PMID:
22716148
4.

Whole plant cannabis extracts in the treatment of spasticity in multiple sclerosis: a systematic review.

Lakhan SE, Rowland M.

BMC Neurol. 2009 Dec 4;9:59. doi: 10.1186/1471-2377-9-59. Review.

5.

Delta-9-tetrahydrocannabinol/cannabidiol (Sativex®): a review of its use in patients with moderate to severe spasticity due to multiple sclerosis.

Syed YY, McKeage K, Scott LJ.

Drugs. 2014 Apr;74(5):563-78. doi: 10.1007/s40265-014-0197-5. Review.

PMID:
24671907
6.

Placebo effects in a multiple sclerosis spasticity enriched clinical trial with the oromucosal cannabinoid spray (THC/CBD): dimension and possible causes.

Di Marzo V, Centonze D.

CNS Neurosci Ther. 2015 Mar;21(3):215-21. doi: 10.1111/cns.12358. Epub 2014 Dec 4. Review.

PMID:
25475413
7.

Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders.

Devinsky O, Cilio MR, Cross H, Fernandez-Ruiz J, French J, Hill C, Katz R, Di Marzo V, Jutras-Aswad D, Notcutt WG, Martinez-Orgado J, Robson PJ, Rohrback BG, Thiele E, Whalley B, Friedman D.

Epilepsia. 2014 Jun;55(6):791-802. doi: 10.1111/epi.12631. Epub 2014 May 22. Review.

8.

Cannabis, pain, and sleep: lessons from therapeutic clinical trials of Sativex, a cannabis-based medicine.

Russo EB, Guy GW, Robson PJ.

Chem Biodivers. 2007 Aug;4(8):1729-43. Review.

PMID:
17712817
9.

THC and CBD oromucosal spray (Sativex®) in the management of spasticity associated with multiple sclerosis.

Sastre-Garriga J, Vila C, Clissold S, Montalban X.

Expert Rev Neurother. 2011 May;11(5):627-37. doi: 10.1586/ern.11.47. Epub 2011 Apr 1. Review.

PMID:
21456949
10.
11.

Delta-9-Tetrahydrocannabinol/Cannabidiol Oromucosal Spray (Sativex®): A Review in Multiple Sclerosis-Related Spasticity.

Keating GM.

Drugs. 2017 Apr;77(5):563-574. doi: 10.1007/s40265-017-0720-6. Review.

PMID:
28293911
12.

[Treatment of spasticity in multiple sclerosis: new perspectives regarding the use of cannabinoids].

Oreja-Guevara C.

Rev Neurol. 2012 Oct 1;55(7):421-30. Review. Spanish.

13.

Cannabis, cannabidiol, and epilepsy--from receptors to clinical response.

Szaflarski JP, Bebin EM.

Epilepsy Behav. 2014 Dec;41:277-82. doi: 10.1016/j.yebeh.2014.08.135. Epub 2014 Oct 1. Review.

PMID:
25282526
14.

Nabiximols in the treatment of spasticity, pain and urinary symptoms due to multiple sclerosis.

Podda G, Constantinescu CS.

Expert Opin Biol Ther. 2012 Nov;12(11):1517-31. doi: 10.1517/14712598.2012.721765. Epub 2012 Sep 7. Review.

PMID:
22954177
15.
16.

THC:CBD spray and MS spasticity symptoms: data from latest studies.

Rekand T.

Eur Neurol. 2014;71 Suppl 1:4-9. doi: 10.1159/000357742. Epub 2014 Jan 22. Review.

PMID:
24457846
17.
18.

Combined cannabinoid therapy via an oromucosal spray.

Perez J.

Drugs Today (Barc). 2006 Aug;42(8):495-503. Review.

PMID:
16969427
19.

Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects.

Russo EB.

Br J Pharmacol. 2011 Aug;163(7):1344-64. doi: 10.1111/j.1476-5381.2011.01238.x. Review.

20.

Treatment of Tourette syndrome with cannabinoids.

Müller-Vahl KR.

Behav Neurol. 2013;27(1):119-24. doi: 10.3233/BEN-120276. Review.

Supplemental Content

Support Center